转自：药明康德

上海，2025年7月7日 – 近日，药明康德在摩根士丹利资本国际公司（MSCI）最新公布的环境、社会及管治（ESG）年度评级结果中，首次获评最高评级“AAA”级，成为A股生命健康行业中首家获此认可的企业。这一成就充分彰显了公司始终践行可持续发展的坚定承诺，更体现了以负责任方式为客户创造长期价值、共建健康未来的决心。

MSCI是全球领先的投资调研公司，为机构投资者提供股票指数和投资组合绩效分析。MSCI ESG评级旨在衡量一家公司对长期的、与财务相关的ESG风险抵御能力。MSCI ESG评级结果从“AAA”（最高）至“CCC”（最低）共分为7个等级，其中“AAA”和“AA”级被视为行业领先者。

药明康德凭借在产品安全与质量、人力资本开发、企业治理等议题的卓越表现，在本次评估周期中获得“AAA”领导力评级。此前，公司已于2021年至2024年期间连续4年保持“AA”评级，体现了其在ESG绩效方面的持续卓越表现。

“我们很荣幸获得MSCI ESG最高评级，这是对药明康德将可持续发展融入公司运营并为社会各方创造长期价值的高度认可。”药明康德联席首席执行官、ESG委员会主席杨青博士表示，“药明康德将持续追求高质量的发展，通过其独特的CRDMO赋能平台，助力客户加速突破性疗法早日问世，造福全球病患。”

作为创新的赋能者、客户信赖的合作伙伴以及全球健康产业的贡献者，药明康德和大多数客户一样，积极践行对可持续发展的承诺，并将其先进的理念融入到公司全球运营的方方面面，不断为社会和环境带来积极的影响。截至目前，公司已连续四年入选道琼斯可持续发展指数（DJSI）；连续三年获得CDP气候变化“A-”级领导力评级、Morningstar Sustainalytics ESG“行业最高评级”及“区域最高评级”；首次获得CDP水安全“A”级领导力评级、EcoVadis企业社会责任评级“金牌”认证。

此外，为进一步深化可持续发展承诺，药明康德持续拓展全球责任实践。公司温室气体减排近期目标成功通过了SBTi审核认证。同时，公司已加入联合国全球契约组织（UNGC），承诺支持全球契约十项原则；并加入制药供应链倡议（PSCI），成为PSCI供应商合作伙伴。

关于药明康德

药明康德（股票代码：603259.SH/2359.HK）是全球医药及生命科学行业值得信赖的合作伙伴和重要贡献者，致力于通过提供一体化、端到端的新药研发和生产服务，推动全球医药健康创新。公司在亚洲、欧洲、北美等地均设有运营基地，依托独特的“CRDMO”业务模式，不断降低研发门槛，助力客户提升研发效率，为患者带来突破性的治疗方案。目前，公司的赋能平台正承载着来自全球30多个国家的约6,000家合作伙伴的研发创新项目，致力于将更多新药、好药带给全球病患，早日实现“让天下没有难做的药，难治的病”的愿景。更多信息，请访问公司网站：www.wuxiapptec.com 

WuXi AppTec Receives MSCI ESG AAA Leader Rating

SHANGHAI, July 7, 2025 - WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, today announced it has achieved the AAA rating – the highest level – from MSCI in its latest annual Environmental, Social, and Governance (ESG) ratings. This is the first time WuXi AppTec has achieved the AAA rating, making it the first A-share listed company in the life science industry to reach this milestone. This achievement underscores WuXi AppTec’s enduring commitment to sustainability and its belief in driving long-term value through responsible growth for a healthier future.

MSCI is a leading provider of critical decision support tools and services for the global investment community. Its ESG ratings assess companies on financially relevant sustainability risks and opportunities, enabling investors to better understand a company’s sustainable development performance and make more informed investment decisions. The MSCI ESG rating system includes seven levels, from AAA (highest) to CCC (lowest), with AAA and AA considered leader ratings.

WuXi AppTec earned the AAA leader rating for its outstanding performance in areas such as Product Safety and Quality, Human Capital Development, and Corporate Governance. Previously, the company maintained an AA rating for four consecutive years, demonstrating consistent leadership in ESG performance. 

“We are honored to receive MSCI’s highest ESG rating,” said Dr. Steve Yang, Co-CEO of WuXi AppTec and Chairman of WuXi AppTec’s ESG Committee. “This recognition reflects our commitment to integrating sustainability across our operations and reaffirms the long-term value we strive to create for all stakeholders. We will continue to pursue high-quality growth through our CRDMO platform and support our customers in developing and delivering innovative therapies to patients worldwide.”

As an enabler of innovation, a trusted partner, and a contributor to the global pharmaceutical and life sciences industry, WuXi AppTec strategically integrates sustainability priorities like most of the customers into its global business operations. The Company has been included in the Dow Jones Sustainability Index (DJSI) for four consecutive years, received an A- Leadership rating in the CDP Climate Change assessment for three years, and has been recognized as an Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics. WuXi AppTec has also earned an A Leadership rating in the CDP Water Security assessment and a Gold Medal in the EcoVadis sustainability rating.

To further its sustainability commitment, WuXi AppTec has received Science Based Targets initiative (SBTi) validation for its near-term emissions reduction targets. The Company is also a participant in the United Nations Global Compact (UNGC), supporting its ten principles, and a supplier partner of the Pharmaceutical Supply Chain Initiative (PSCI).

About WuXi AppTec

WuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries, providing R&D and manufacturing services that help advance healthcare innovation. With operations across Asia, Europe, and North America, we offer an integrated, end-to-end services through our unique CRDMO (Contract Research, Development, and Manufacturing Organization) platform. We are privileged to work alongside nearly 6,000 partners across 30+ countries, supporting their efforts to bring breakthrough treatments to patients. Guided by our vision that every drug can be made and every disease can be treated, we are committed to advancing breakthroughs for patients—one collaboration at a time. Learn more at www.wuxiapptec.com.

（转自：药明康德）